| Ytd | 10.00% | |
| 1y | -15.38% |
| Open | 1.56 | Prev Close | 1.56 | Low | 1.53 | High | 1.62 | Mkt Cap | 69.48M |
| Vol | 264.75K | Avg Vol | 815.42K | EPS | -1.02 | P/E | -1.53 | Forward P/E | 2.57 |
| Beta | -0.83 | Short Ratio | 1.22 | Inst. Own | 0.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 1.76 | 200-d Avg | 1.63 | 1yr Est | 12.67 |
OSTX News
Roth Capital analyst Adam Walsh initiates coverage on OS Therapies (AMEX:OSTX) with a Buy rating
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs p
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the
OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no ne
Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the pric
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst con
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune
New patent application covers treatment-emergent immune signature related to 'turning cold tumor
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst con
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with ex
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated
